Interestingly, neutralizing antibodies directed against TAMs-derived Interleukin-10 (IL-10) significantly enhance the sensitivity of BC cells due to the reported relationship between the IL-10/STAT3/Bcl-2 signaling pathway and the BC cell resistance to paclitaxel treatment (63). Here, BCL2 is linked to breast cancer.